Hamlet BioPharma (HAMLET) Q2 2025 earnings summary

Executive summary

• Completed three successful Phase II studies showing efficacy in bladder cancer, bladder pain syndrome, and recurrent acute cystitis.

• Alpha1H demonstrated strong tumor-killing effects and clinical efficacy in bladder cancer with positive FDA dialogue and Fast Track Designation.

• Immunotherapy with anakinra proved as effective as antibiotics for bacterial infections, reducing symptoms and recurrence.

• Raised SEK 26.8 million through a directed rights issue to support ongoing development.

Financial highlights

• Net sales were KSEK 0 for both the quarter and first half, unchanged from the previous year.

• Group loss before tax for Q2 was KSEK -14,387 (vs. -9,154 last year); first half loss before tax was KSEK -24,651 (vs. -17,982).

• Cash and cash equivalents at quarter-end were KSEK 30,391 (vs. 6,205 last year).

• Equity/assets ratio improved to 92.8% (vs. 84.5% last year).

Outlook and guidance

• Focus on advancing Alpha1H to Phase III trials for bladder cancer, leveraging Fast Track status.

• Continued development of immunotherapy for infections and pain, with further analyses and publications planned.

• Ongoing search for commercial partners for core assets and preclinical projects.